- Home
- BYSI vs NSPR Comparison
BYSI vs NSPR Comparison
Compare BYSI & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- NSPR
- Stock Information
- Founded
- BYSI 2010
- NSPR 2005
- Country
- BYSI United States
- NSPR Israel
- Employees
- BYSI N/A
- NSPR N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- BYSI Health Care
- NSPR Health Care
- Exchange
- BYSI Nasdaq
- NSPR Nasdaq
- Market Cap
- BYSI 72.1M
- NSPR 63.0M
- IPO Year
- BYSI 2017
- NSPR N/A
- Fundamental
- Price
- BYSI $1.79
- NSPR $3.19
- Analyst Decision
- BYSI
- NSPR Strong Buy
- Analyst Count
- BYSI 0
- NSPR 2
- Target Price
- BYSI N/A
- NSPR $4.75
- AVG Volume (30 Days)
- BYSI 10.8K
- NSPR 50.3K
- Earning Date
- BYSI 01-01-0001
- NSPR 03-05-2025
- Dividend Yield
- BYSI N/A
- NSPR N/A
- EPS Growth
- BYSI N/A
- NSPR N/A
- EPS
- BYSI N/A
- NSPR N/A
- Revenue
- BYSI $1,876,000.00
- NSPR $6,821,000.00
- Revenue This Year
- BYSI N/A
- NSPR $13.36
- Revenue Next Year
- BYSI N/A
- NSPR $49.64
- P/E Ratio
- BYSI N/A
- NSPR N/A
- Revenue Growth
- BYSI 21.03
- NSPR 24.70
- 52 Week Low
- BYSI $1.05
- NSPR $1.81
- 52 Week High
- BYSI $4.00
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- BYSI 56.87
- NSPR 63.51
- Support Level
- BYSI $1.61
- NSPR $2.60
- Resistance Level
- BYSI $1.88
- NSPR $3.11
- Average True Range (ATR)
- BYSI 0.10
- NSPR 0.28
- MACD
- BYSI 0.00
- NSPR 0.05
- Stochastic Oscillator
- BYSI 66.67
- NSPR 87.15
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.